Physician profile
Thomas Westbrook
NPI 1396716775
$809,604.09
in general payments reported to CMS, 2019-2025
43 companies · $80K in 2025
The $80K reported for 2025 was more than what 97% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146K · 2020: $50K · 2021: $81K · 2022: $108K · 2023: $167K · 2024: $177K · 2025: $80K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $320K · Consulting Fee: $59K · Travel and Lodging: $24K · Food and Beverage: $21K · Education: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $319,985.99 |
| Consulting Fee | $59,173.34 |
| Travel and Lodging | $23,664.13 |
| Food and Beverage | $21,375.13 |
| Education | $276.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $357,380.37 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Regeneron Healthcare Solutions, INC. | $138,600.12 | 2019-2025 | Dupixent |
| Pharming Healthcare, INC. | $89,861.61 | 2019-2025 | Ruconest |
| Glaxosmithkline, LLC. | $66,108.04 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $63,114.55 | 2019-2025 | |
| Optinose US, INC. | $18,949.69 | 2019-2024 | |
| Csl Behring | $18,563.87 | 2019-2025 | Andembry, Hizentra, Haegarda |
| Amgen INC. | $17,420.16 | 2021-2025 | Tezspire |
| Genentech USA, INC. | $16,168.90 | 2019-2025 | Xolair |
| Grifols USA, LLC | $7,070.85 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Hikma Pharmaceuticals USA | $5,075.08 | 2023-2024 | Ryaltris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,293.68 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $2,077.68 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $818.21 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Pfizer INC. | $587.05 | 2019-2024 |
Show all 42 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Westbrook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.